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Abstract
Several studies have identified copy number variants (CNVs) as responsible for cardiac diseases associated with sudden
cardiac death (SCD), but very few exhaustive analyses in large cohorts of patients have been performed, and they have been
generally focused on a specific SCD-related disease. The aim of the present study was to screen for CNVs the most prevalent
genes associated with SCD in a large cohort of patients who suffered sudden unexplained death or had an inherited cardiac
disease (cardiomyopathy or channelopathy). A total of 1765 European patients were analyzed with a homemade algorithm
for the assessment of CNVs using high-throughput sequencing data. Thirty-six CNVs were identified (2%), and most of
them appeared to have a pathogenic role. The frequency of CNVs among cases of sudden unexplained death, patients with a
cardiomyopathy or a channelopathy was 1.4% (8/587), 2.3% (20/874), and 2.6% (8/304), respectively. Detection rates were
particularly high for arrhythmogenic cardiomyopathy (5.1%), long QT syndrome (4.7%), and dilated cardiomyopathy
(4.4%). As such large genomic rearrangements underlie a non-neglectable portion of cases, we consider that their analysis
should be performed as part of the routine genetic testing of sudden unexpected death cases and patients with SCD-related
diseases.




1 Cardiovascular Genetics Center, University of Girona-IdIBGi,
Girona, Spain
2 Centro de Investigación Biomédica en Red. Enfermedades
Cardiovasculares (CIBERCV), Madrid, Spain
3 Gendiag.exe SL, Barcelona, Spain
4 Department of Cardiology, Hospital General Universitario
Gregorio Marañón, Madrid, Spain
5 Arrhythmia Unit, Hospital Sant Joan de Déu, University of
Barcelona, Barcelona, Spain
6 Arrhythmia Unit, Hospital Clínic, Universitat de Barcelona,
Barcelona, Spain
7 Inherited Cardiac Diseases Unit. Department of Cardiology,
Hospital Universitario Puerta de Hierro, Francisco de Vitoria
University, Madrid, Spain
8 Hospital Universitari Vall d’Hebron, Barcelona, Spain
9 Hospital Universitario Reina Sofía, Córdoba, Spain
10 Genetics Unit, Hospital Universitario de Móstoles, Madrid, Spain
11 Hospital Miguel Servet, Zaragoza, Spain
12 Molecular DX Unit, Hospital Universitario de Canarias,
Santa Cruz de Tenerife, Spain
13 Hospital Vírgen del Rocío, Sevilla, Spain
14 Medical Sciences Department, School of Medicine, University of
Girona, Girona, Spain










More than four million people around the world die every
year because of sudden cardiac death (SCD). The most
common cause of SCD in adults is coronary heart disease,
but arrhythmogenic cardiac diseases are the leading cause in
population younger than 35 years old. In this latter group,
most SCDs are due to cardiomyopathies—mainly hyper-
trophic cardiomyopathy (HCM), dilated cardiomyopathy
(DCM), arrhythmogenic cardiomyopathy (AC), and left
ventricular non-compaction (LVNC), or due to electrical
abnormalities without structural heart defects, commonly
known as channelopathies—predominantly long QT syn-
drome (LQTS), short QT syndrome (SQTS), catecholami-
nergic polymorphic ventricular tachycardia (CPVT), and
Brugada syndrome (BrS) [1].
Despite the improvements in genetic diagnosis, closely
linked to the development of high-throughput sequencing
(HTS) technology, the percentage of cases that remain
unexplained after genetic screening is still high, ranging
from 20% to 80% depending on the disease [2]. Causality in
unresolved cases may be explained by variants in as of yet
non-associated genes, regulatory regions, splice sites, epi-
genetic alterations, or structural variants (not detectable by
traditional Sanger sequencing). In the last 10 years, scien-
tists have identified abundant and ubiquitous structural
variants in the human genome, both in normal population
and in disease groups. Among them stand out copy number
variants (CNVs), which have been traditionally defined as
DNA segments larger than one kilobase (kb) that present
variable copy number in comparison with a reference gen-
ome. In the last years, several authors consider a CNV any
imbalance larger than 50 base pairs [3] (bp) (this latter
criterion is the one followed in the present work). Evidence
supporting a role of CNVs in SCD-related pathologies has
been reported, but robust studies with large cohorts of
patients and multiple genes being screened have only been
performed for specific SCD-related diseases [4–18].
The lack of information on prevalence of CNVs in SCD
and related diseases encouraged our group to shed some
light on this topic. We have analyzed CNVs in the most
prevalent genes associated with SCD in a large cohort of
patients diagnosed with a cardiomyopathy or a channelo-
pathy, and patients who died suddenly with a suspected




Our cohort includes 1765 unrelated European patients, and
is divided in three subgroups: (a) 587 post-mortem blood
samples from SUD patients (23 of them were cases of
sudden infant death syndrome (SIDS)) (all cases were aged
<50 y.o. and had a non-conclusive cause of death after a
complete autopsy, including toxicological analyses and
macroscopic and microscopic analysis of the heart); (b) 874
patients clinically diagnosed with a cardiomyopathy: 591
HCM, 136 DCM, 118 AC, and 29 LVNC; and (c) 304
patients diagnosed with a channelopathy: 151 BrS, 127
LQTS, 7 SQTS, and 19 CPVT (Fig. 1a). Samples were
referred from 11 hospitals from Spain and from Institute of
Legal Medicine of Catalonia. The study was approved by
the Ethics Committee of Hospital Universitari Dr. Josep
Trueta (Girona, Spain) and conforms to the principles out-
lined in the Declaration of Helsinki.
Fig. 1 Cohort distribution a and frequency of CNVs by pathology b.
AC arrhythmogenic cardiomyopathy, AF affects function, BrS Bru-
gada syndrome, DCM dilated cardiomyopathy, HCM hypertrophic
cardiomyopathy, LQTS long QT syndrome, LVNC left ventricular
non-compaction, NAF does not affect function, PAF probably affects
function, PNAF probably does not affect function, SIDS sudden infant
death syndrome, SQTS short QT syndrome, SUD sudden unexplained
death, VUS variant of unknown significance
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Custom sequencing panel design and library
preparation
Two custom sequencing panels, which included the coding
regions and intronic boundaries of 55 or 78 genes associated
with SCD, were used. The genes screened in each panel and
the reference isoforms analyzed are listed in Table 1.
Coordinates of sequence data were based on UCSC human
genome version GRCh37/hg19. The 55-gene panel, which
included the UTR (Untranslated Region) sequences for
some genes, covered 432,512 kb of the human genome and
was used for the screening of 701 patients. The 78-gene
panel did not include UTR regions, covered 410,308 kb and
was used for 1064 patients. A biotinylated com-
plementary RNA probe solution was used to capture the
regions of interest (Agilent Technologies, Santa Clara, CA,
USA). Probes were designed and optimized by Gendiag.exe
SL. Both custom enrichment gene designs are commercia-
lized by Ferrer inCode as SudD inCode®.
For library preparation, genomic DNA was extracted
with Chemagic Magnetic Separation Module I (Perki-
nElmer, Waltham, MA, USA) from post-mortem or fresh
whole blood samples. DNA was fragmented with Bior-
uptor® (Diagenode, Seraing, Belgium) and libraries were
prepared following the SureSelect XT Target Enrichment
System for Illumina Paired-End Sequencing Library pro-
tocol (Agilent Technologies). Indexed libraries were
sequenced in 10-sample pools per cartridge. Paired-end
sequencing process was performed on a MiSeq platform
(Illumina, San Diego, CA, USA), with a read length of 2 ×
76 bp.
Detection of genetic variants
For the analysis of single-nucleotide variants (SNVs) and
small insertions or deletions (indels), an algorithm devel-
oped by Gendiag.exe SL was used. The algorithm follows
four analytic steps: (i) adaptors and low quality bases
trimming; (ii) mapping with Burrows-Wheeler Aligner -
Maximum Exact Match; (iii) SNV and indel detection with
SAMtools v.1.2, together with an ad hoc developed script
—intronic positions up to 6 bp are interrogated; and (iv)
SNVs and indels annotation with dbSNP, Exome Sequen-
cing Project, 1000 Genomes, Exome Aggregation Con-
sortium, Human Gene Mutation Database (HGMD),
ClinVar, Ensembl and in home database IDs. Only non-
synonymous variants with a minor allele frequency <1% in
general population were reported and confirmed by Sanger
sequencing.
The CNV detection was performed with an ad hoc
developed algorithm divided in seven major steps: (i) raw
coverage extraction from BAM files (using BEDtools
v2.23.0); (ii) quality metrics collection and coverage cor-
relation between samples (correlation coefficients >0.97
were expected for comparable samples; those samples dis-
playing a generalized dispersion were removed from ana-
lysis and, therefore, not included in the cohort); (iii) raw
coverage normalization by library size and GC (guanine-
cytosine) content correction per region; (iv) log2-ratio cal-
culation for every sample within each region of interest
using a dynamic baseline built with normalized coverages
derived from the other samples being analyzed; (v) copy
number estimation: if the ratio fell outside a signal-to-noise
window (±3 SD) and was greater or lower than the dupli-
cation or deletion cutoffs (0.45 and −0.8, respectively), a
Table 1 Genes screened in the 55- and 78-gene panels and the transcript reference sequences used
Genes
55-gene panel ACTC1 (NM_005159.4), ACTN2 (NM_001103.3), ANK2 (NM_001148.4), CACNA1C (NM_001129827.1), CACNB2
(NM_201596.2), CASQ2 (NM_001232.3), CAV3 (NM_033337.2), CRYAB (NM_001885.2), CSRP3 (NM_003476.3), DES
(NM_001927.3), DMD (NM_004006.2), DSC2 (NM_024422.4), DSG2 (NM_001943.4), DSP (NM_004415.3), EMD
(NM_000117.2), FBN1 (NM_000138.4), GLA (NM_000169.2), GPD1L (NM_015141.3), HCN4 (NM_005477.2), JPH2
(NM_020433.4), JUP (NM_002230.2), KCNE1 (NM_000219.3), KCNE2 (NM_172201.1), KCNH2 (NM_000238.3), KCNJ2
(NM_000891.2), KCNQ1 (NM_000218.2), LAMP2 (NM_002294.2), LDB3 (NM_001080116.1), LMNA (NM_170707.2),
MYBPC3 (NM_000256.3), MYH6 (NM_002471.3), MYH7 (NM_000257.3), MYL2 (NM_000432.3), MYL3 (NM_000258.2),
MYOZ2 (NM_016599.4), PDLIM3 (NM_014476.5), PKP2 (NM_004572.3), PLN (NM_002667.4), PRKAG2 (NM_016203.3),
RYR2 (NM_001035.2), SCN4B (NM_174934.3), SCN5A (NM_198056.2), SGCA (NM_000023.3), SGCB (NM_000232.4),
SGCD (NM_000337.5), TAZ (NM_000116.4), TCAP (NM_003673.3), TGFB3 (NM_003239.4), TGFBR2 (NM_003242.5),
TNNC1 (NM_003280.2), TNNI3 (NM_000363.4), TNNT2 (NM_001001430.2), TPM1 (NM_001018005.1), TTN
(NM_133378.4), VCL (NM_014000.2)
78-gene panel Genes included in the 55-gene panel (except SGCA and SGCB)+ ABCC9 (NM_005691.3), AKAP9 (NM_005751.4), BAG3
(NM_004281.3), CACNA2D1 (NM_000722.3), FKTN (NM_001079802.1), KCND3 (NM_004980.4), KCNE1L
(NM_012282.3), KCNE3 (NM_005472.4), KCNJ5 (NM_000890.4), KCNJ8 (NM_004982.3), MYPN (NM_032578.3), NEBL
(NM_006393.2), NEXN (NM_144573.3), NOS1AP (NM_001164757.1), RANGRF (NM_016492.4), RBM20
(NM_001134363.2), SCN1B (NM_001037.4, NM_199037.4), SCN2B (NM_004588.4), SLMAP (NM_007159.4), SNTA1
(NM_003098.2), TMEM43 (NM_024334.2), TMPO (NM_001032283.2), TP63 (NM_003722.4), TRDN (NM_006073.3),
TRPM4 (NM_017636.3)
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CNV was inferred (to avoid artifacts caused by abnormally
long insert sizes in regions with short nearby exons, the
algorithm scanned the surrounding introns for discordant
read pairs—if no breakpoints were detected, the signal was
discarded due to an anomalous gain/loss of coverage not
associated with the presence of a structural variation); (vi)
annotation with HGMD, ClinVar, DECIPHER, Database of
Genomic Variants, 1000 Genomes, and ClinGen (if the
potential CNV was present in global population and healthy
individuals with a frequency >1%, it was considered a
polymorphism and was not reported); and (vii) CNV quality
score generation, which takes into account sample char-
acteristics (total number of reads, enrichment of the regions
of interest and differences of insert sizes among samples),
signal behavior (robustness through deletion/duplication
cutoffs and noise), and region characteristics (anomalous
GC percentage, abnormal allelic frequencies for Sin-
gle Nucleotide Polymorphisms detected in the potentially
altered region, and length and distance to nearby regions).
Identified CNVs were confirmed by multiplex ligation-
dependent probe amplification (MLPA) (MRC-Holland,
Amsterdam, The Netherlands) or quantitative polymerase
chain reaction (qPCR) with QuantStudio 7 Flex System and
Power Up Sybr Green master mix (Thermo Fisher Scien-
tific, Waltham, MA, USA), following manufacturer’s
recommendations. Confirmed CNVs were submitted to
DECIPHER.
Classification of genetic variants
SNVs and indels were classified as variants that: affect
function (AF), probably affect function (PAF), probably
does not affect function (PNAF), does not affect function
(NAF), or variants of uncertain significance (VUS);
according to the recommendations of the Human Genome
Variation Society. They are equivalent to the terms used by
the American College of Medical Genetics and Genomics
and the Association for Molecular Pathology: pathogenic
variant, likely pathogenic variant, likely benign variant,
benign variant, or variant of uncertain significance,
respectively [19].
Regarding CNVs, a CNV was considered a variant that
AF if: (a) it had been previously reported as pathogenic for
patient’s disease (or for SUD cases, if the reported disease is
compatible with a structurally normal heart—this remark
applies for all the following classifications); (b) it was a
deletion in/of a gene where loss of function is a known
mechanism of patient’s disease; (c) it was an intragenic in
tandem duplication (not involving the last exon of the gene)
in a gene where loss of function is a known mechanism of
disease; or (d) it was a whole gene duplication in a gene for
which triplosensitivity is known to cause patient’s disease.















































































































































































































































































































































































































































































































































































































































1020 J. Mates et al.
deletion in/of a gene associated with the observed disease or
an intragenic duplication (not involving the last exon of the
gene) in a gene associated with the disease, and the variant
was absent from controls; or (b) the CNV cosegregated with
the disease in >5 affected family members. A CNV was
considered a variant that NAF if previously described as
benign, and PNAF if: (a) identified in >10 individuals in
general population (for whole gene deletions/duplications,
cases of general population involving contiguous genes
were considered for comparison), or (b) the CNV did not
cosegregate with disease in the family. All remaining sce-
narios were classified as VUS. Exons involved in CNVs
were numbered according to genomic reference sequences
(NG_), detailed in Table 2.
Statistical analysis
Comparisons between variables were performed using the
chi-square test, with STATA/IC 13.1 for Windows. Two-
sided p-values < 0.05 were considered significant.
Results
Study cohort
For the 1765 patients of the cohort, the mean age at clinical
diagnosis was of 39.8 ± 19.8 y.o. The majority of patients
were males (68%), and their age at diagnosis was not sig-
nificantly different from that of females.
Genetic screening
An exhaustive screening for SNVs and indels was carried
out in the entire cohort. However, since the leading interest
of the present work was to explore the frequency of CNVs
in SCD and related pathologies, we only reported SNVs and
indels present in those samples with CNVs (Table 2).
A total of 79 CNVs were identified in 78 out of the 1765
patients studied. Thirty-six of these variants were confirmed
by MLPA or qPCR (in 36 different patients) (Table 2 and
Fig. 2). The remaining 43 signals resulted to be false
positives of the HTS methodology used (false discovery
rate of 54.4%). Thus, the detection rate for large genomic
imbalances in our cohort was 2%. The detected CNVs
consisted of 18 deletions and 18 duplications, and were
identified in the genes described in Table 2 (DECIPHER ID
for each case is also specified in Table 2). All variants were
heterozygous or hemizygous. According to our classifica-
tion criteria, 14 CNVs were considered AF, 6 PAF, 14
VUS, and 2 PNAF. The majority of the CNVs identified
involved several exons. The smallest CNV detected was a
104-bp deletion including exon 28 of ABCC9 gene (case
S21), and the largest one was a 194-kb duplication invol-
ving >200 exons of TTN gene (case S28). It is important to
specify that as we used targeted gene panels for the
screening, no breakpoints could be defined for the detected
CNVs, as most of them fell into intronic or intergenic
regions excluded from the analysis. Consequently, the size
of the detected CNVs could be larger than reported.
Among SUD cases, the frequency of patients with CNVs
was 1.4% (8/587 patients) (Table 3 and Fig. 1b), 0.5% if we
only consider variants that AF or PAF (1 and 2 CNVs,
respectively). This cohort included 23 cases of SIDS, and 1
of them (4.3%) had a CNV, which was classified as VUS.
Regarding cardiomyopathies, we detected a frequency of
CNVs in our series of: 1.2% for HCM (7/591 patients; 4 AF
and 3 PAF), 4.4% for DCM (6/136 patients; 3 AF, 2 VUS,
and 1 PNAF), 5.1% for AC (6/118 patients; 2 AF, 3 PAF,
and 1 VUS), and 3.4% for LVNC (1/29 patients; 1 VUS)
(Fig. 1b). The HCM subgroup includes 303 patients already
published by our group [18]. In relation to channelopathies,
the frequency for each disease in our series was: 4.7% for
LQTS (6/127 patients; 4 AF, 1 PAF, and 1 VUS), 1.3% for
BrS (2/151 patients; 2 VUS), 0% for SQTS (0/7 patients),
and 0% for CPVT (0/19 patients) (Fig. 1b).
Algorithm validation
Prior to the realization of the present work, a validation of
the algorithm for the detection of CNVs was performed
using a cohort of 108 full-screened cardiovascular disease
patients. Among these patients, there were 16 carriers of
CNVs (the remaining patients were negative for these
structural variants). The CNV sizes of the validation set
ranged from 1 to 15 exons, with minimal known sizes of
123 bp and 40.1 kb, respectively. The algorithm achieved a
sensitivity of 100% and a specificity of 91%. The corre-
sponding positive predicting value was 64% and, therefore,
the false discovery rate was 36%. In order to compare our
algorithm with other CNV detection softwares, the same
validation cohort was analyzed with CONTRA v.2.0.8 [20]
and CNVKIT v.0.8.6 [21], for which effectiveness and
reliability have been previously widely proved [22]. The
best results were those achieved with our algorithm and
CNVKIT, both in terms of accuracy (99.9%, whereas for
CONTRA it was 99.6%) and sensitivity (100%, whereas for
CONTRA it was 87.3%). Moreover, our algorithm gave
superior precision in comparison with CNVKIT and
CONTRA (85.9% versus 83.3% and 75%, respectively).
HTS panel performance
The average call rate achieved at 30× with the custom
enrichment gene designs of 55 and 78 genes was 99.70%
and 99.82%, respectively. The median percentage of reads
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overlapping our target regions was 48% for the first panel
and 66% for the second one. The median coverage per
sample was 870 and 679, respectively. If a region did not
reach a minimum coverage of 30×, conventional Sanger
sequencing was performed for that region.
Discussion
Several studies have identified CNVs as causative of cardiac
diseases associated with SCD [4–18]. However, exhaustive
analysis of multiple genes in large cohorts of patients has
never been performed for most SCD-related diseases.
Motivated by this lack of information, in the present study
we screened for CNVs the main genes associated with SCD
using HTS technology in a large cohort of SUD cases and
patients diagnosed with a cardiomyopathy or a
channelopathy.
Among SUD cases, the frequency of patients with CNVs
was 1.4%. These results cannot be compared with pre-
viously published studies, as the present work is the first
screening for CNVs in a large series of SUD cases. There is
Fig. 2 Graph of four of the CNVs detected in our cohort (log2 ratios).
a Deletion from exons 9 to 24 of DSP in a patient with arrhythmogenic
cardiomyopathy (S26, dark blue). b Deletion of exons 8 and 9 of
KCNQ1 found in three long QT syndrome patients (S3 shown in the
graph, brown). c Duplication from exons 8 to 10 of PKP2 identified in
three arrhythmogenic cardiomyopathy patients (S22 shown in the
graph, red). d Complex rearrangement involving exons 4, 5, and 8 of
TNNI3 in a sudden unexplained death case (S33, light green)
Table 3 Summary of the CNVs identified
CNVs AF PAF VUS PNAF NAF
SUD 1.4% (8/587) 1/8 2/8 4/8 1/8 0/8
SUD/SIDS 4.3% (1/23) 0/1 0/1 1/1 0/1 0/1
HCM 1.2% (7/591) 4/7 0/7 3/7 0/7 0/7
DCM 4.4% (6/136) 3/6 0/6 2/6 1/6 0/6
AC 5.1% (6/118) 2/6 3/6 1/6 0/6 0/6
LVNC 3.4% (1/29) 0/1 0/1 1/1 0/1 0/1
BrS 1.3% (2/151) 0/2 0/2 2/2 0/2 0/2
LQTS 4.7% (6/127) 4/6 1/6 1/6 0/6 0/6
SQTS 0% (0/7) – – – – –
CPVT 0% (0/19) – – – – –
AC arrhythmogenic cardiomyopathy, AF affects function, BrS Brugada
syndrome, CPVT catecholaminergic polymorphic ventricular tachy-
cardia, DCM dilated cardiomyopathy, HCM hypertrophic cardiomyo-
pathy, LQTS long QT syndrome, LVNC left ventricular non-
compaction, NAF does not affect function, PAF probably affects
function, PNAF probably does not affect function, SIDS sudden infant
death syndrome, SUD sudden unexplained death, VUS variant of
unknown significance
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only one previous publication involving the screening for
CNVs in SUD/SIDS cases [4]. The authors performed
array-based comparative genomic hybridization in 27 cases
of SIDS, and detected 3 CNVs. However, these CNVs were
large (all of them >240 kb, involving several genes) and at
least one could be associated with a syndromic phenotype.
Regarding cardiomyopathies, we detected a frequency of
CNVs in our series of: 1.2% for HCM, 4.4% for DCM,
5.1% for AC, and 3.4% for LVNC. Recently, Ceyhan-
Birsoy et al. published a study of similar characteristics and
reported the following frequencies: 0.56% for HCM, 0.6%
for DCM, 1% for AC, and 1.9% for LVNC [17]. Lopes
et al. also published in 2015 a comprehensive screening for
CNVs in HCM patients, and reported a frequency of 0.8%
[13]. Although detection rates seem to be higher in our
cohort, differences are only statistically significant for
DCM, which may be due to cohort characteristics. No
further studies including a comprehensive screening for
CNVs in large series of patients with cardiomyopathy have
been performed, but there are several additional reports of
CNVs in patients with DCM [5, 6, 9, 12,], AC [15], and
HCM [18].
In relation to channelopathies, the frequency of CNVs in
our series was: 4.7% for LQTS, 1.3% for BrS, and 0% for
SQTS and CPVT. Previously published series involving
LQTS patients consist of the study of exclusively 2–5 genes
(KCNQ1, KCNH2, KCNE1, KCNE2, and/or SCN5A), with a
CNV detection rate of 2–11.5% [8, 10,], which is compa-
tible with our results. In our series, five out of the six CNVs
detected in LQTS patients were detected in these five genes,
and were considered variants that AF/PAF. Patient S3 was
published in 2014 as a case report [10]. For BrS, only the
work performed by our group including the screening for
SCN5A and for some cases BrS-minor genes in BrS patients
has been published (63 cases screened by HTS are included
in the present study), and a single duplication in SCN5A was
detected [16]. An intragenic deletion in SCN5A was also
previously reported in a BrS patient [7]. For CPVT, several
CNVs in RYR2 have been identified [11, 14,], but other
CPVT-related genes have never been screened for large
genomic imbalances up to that time. On the other hand,
studies involving the screening for CNVs in SQTS patients
have never been previously published.
Accordingly, the CNV detection rate is variable for the
different groups studied, ranging from 0% to 5.1% in our
cohort. Although the knowledge of the role of CNVs in
most SCD-related diseases is scarce, our results are com-
patible with those already published. As CNVs underlie a
non-neglectable portion of cases, we consider that their
analysis should be performed as part of the routine genetic
testing of SUD cases and patients with SCD-related dis-
eases. This especially applies for patients with cardiomyo-
pathies and LQTS, as the CNV detection rate among these
patients is particularly high. Further studies, mainly those
focused in the poorly studied cardiac disease groups, will
allow to improve the data on the prevalence of CNVs in
these populations. Although large genomic imbalances have
never been reported for some of the diseases included in the
present work, CNVs may be the genetic cause for a portion
of these patients. It is noteworthy that the identification of a
disease-causing variant in a patient is crucial for diagnosis
confirmation in borderline cases, early management of at-
risk family members, and avoidance of unnecessary follow-
up of non-carriers. Moreover, if genetic testing for SNVs
and indels is performed using HTS technologies, the
screening for CNVs requires no additional costs (apart from
those associated with confirmation tests).
Interestingly, all the CNVs classified as variants that AF
or PAF in our series were identified in patients without
SNVs or indels considered responsible of the observed
phenotype. Eight of these patients were sequenced with the
55-gene panel, whereas 12 with the 78-gene panel
(Table 2). This suggests that the non-identification of any
variant that AF or PAF is not directly related to the panel
used. However, for the patients screened with the 55-gene
panel, we cannot exclude the presence of SNVs and/or
indels classified as AF or PAF in the not-screened genes.
Regarding the characteristics of the detected CNVs, most
of them were novel (Table 2), which may be partly
explained by the reduced number of studies focused on the
screening of these genes and the low resolution of the
techniques used for genotyping structural variants in 1000
Genomes project. On the other hand, seven recurrent CNVs
have been identified in our cohort: deletion of exons 8 and 9
of KCNQ1, duplication of exons 8–10 of PKP2, deletion of
exon 1 of PKP2, deletion of exons 21–23 of DSP, dupli-
cation of KCNE1 and KCNE2, deletion of exon 2 of PLN,
and duplication of exons 2–11 of CASQ2 (Table 2). These
recurrent CNVs may be the result of a founder effect or due
to rearrangement flanking regions particularly rich in
interspersed repeats, low complexity DNA sequences, or
mobile genetic elements, which are genetic features that
tend to generate genomic instability and promote the
apparition of DNA rearrangements [23].
Family segregation studies could be performed for
patients S3 [10] and S18 [18]. Cosegregation with complete
penetrance was observed in both cases (two and one
affected family members, respectively). The relative of
patient S18 harboring the deletion of MYBPC3 was also
carrier of the variants TTN_c.77716C>T and
NEBL_c.326T>C, but not the variant TTN_c.6163G>A.
For many diseases, HTS technology has been progres-
sively incorporated into clinical diagnosis, but high quality
analysis is required to ensure the reliability of the results.
Our CNV detection method offers high reliability for the
detection of such genomic rearrangements when using
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custom sequencing panels (sensitivity of 100%, specificity
of 91% and positive predictive value of 64%). Compared
with other widely used algorithms for detection of CNVs
from HTS data (CONTRA [20] and CNVKIT [21]), our
algorithm is the one with higher accuracy, sensitivity, and
precision altogether. In part, this is probably due to the
capture probe optimization step during the HTS panel
design. Our custom gene panel design and the optimized
probe distribution (mainly in regions difficult to be properly
sequenced) result in samples that exhibit both high coverage
homogeneity across all captured regions and high median
coverage per sample, despite being short read sequences
obtained from a moderate capacity platform. With this
sample quality, our CNV detection algorithm shows a high
sensitivity with an assumable number of false positives, an
imperative fact for its implementation in the routine of a
genetic diagnosis laboratory. Moreover, the algorithm is
able to detect single and multiple exon deletions/duplica-
tions. The detection of small single exon alterations is
particularly important, as they tend to be discriminated in
exome-sequencing detection assays [13, 24,]. In the present
cohort, we had a false discovery rate of 54.4%. The reason
for such high frequency of false positives was to avoid as
much as possible false negatives, being aware of the lim-
itations of short read sequencing and taking into account
that samples were screened for diagnosis purposes. We
selected some suspicious signals for validation even though
the CNV detection algorithm gave them a low quality score.
This resulted in an attempt to validate a set of signals
(usually exons with extreme GC content and too far from
other exons to detect breakpoints) that turned out to be false
positives.
Finally, we believe that both interpretation and clinical
translation of genetic data is the current challenge for
geneticists as well as cardiologists. Current CNV inter-
pretation guidelines are focused on the interpretation of
large genomic rearrangements, generally involving multiple
contiguous genes [25, 26,]. Detailed recommendations for
the interpretation of intragenic CNVs do not exist, although
they need special considerations. For example, duplications
are generally considered to be less deleterious than deletions
[25], but an intragenic duplication may disrupt a gene in the
same way a deletion does. In an attempt to help in the
interpretation of such rearrangements, in the present work
we describe several criteria for their classification. The
mainstay is if loss-of-function of a particular gene is a
known mechanism of patient’s disease, which is also the
stronger criterion for classifying variants as pathogenic
according to the standards and guidelines for the inter-
pretation of sequence variants [19]. If this is the case, any
deletion or tandem duplication (not involving the last exon
of the gene) within this gene should be considered to affect
its normal function, as it will disrupt gene function by
leading to a complete absence of the gene product by lack of
transcription or nonsense-mediated decay of the altered
transcript [19] (if a tandem duplication involves the last
exon of a gene, this gene may have normal expression).
This statement concerns exclusively confirmed tandem
duplications, but it has to be noticed that the 83% of the
duplications are tandem duplications in direct orientation
[27]. On the other hand, it is important to remember the
importance of having family members of patients with
CNVs for its proper classification. Cosegregation of a CNV
with disease in multiple affected family members supports
that the variant affects the normal function of a gene and no
cosegregation supports benignity, thus reducing the pro-
portion of VUS. It is also worth mentioning that a portion of
the CNVs considered VUS in our cohort because the altered
gene had not been previously related to the patient’s disease
could be in fact variants that AF or PAF, because it is
widely known that the same gene (and even the same
genetic variant) can be associated with different SCD-
related diseases [28].
In summary, we report the frequency of CNVs in SUD
cases and patients diagnosed with a cardiomyopathy or a
channelopathy, and interpret the results for its translation
into clinics. Although CNVs only explain a small portion of
cases for most SCD-related diseases, we support the
screening for such rearrangements as part of routine clinical
testing with the ultimate aim of identifying the cause of the
patient’s disease and providing an appropriate clinical
assessment, genetic counseling, and preventive measures
for patients and their relatives.
Acknowledgements We acknowledge the CIBERCV, an initiative of
the Instituto de Salud Carlos III/Spanish Ministry of Economy and
Competitiveness (Fondos FEDER). The sources of funds supporting
the present work are: Fundació “Obra social La Caixa” (IP: Ramon
Brugada), Instituto de Salud Carlos III—Fondo Investigación Sanitaria
FIS PI14/01773 (IP: Ramon Brugada), Sociedad Española de Cardi-
ología (Proyecto Investigación Básica Cardiología 2015 de los Socios
Estratégicos SEC) (IP: Oscar Campuzano). Dr. JM is a beneficiary of
the PFIS predoctoral fellowship FIS.09.01.06/13–146, from Instituto
de Salud Carlos III.
Compliance with ethical standards
Conflict of interest RB is consultant of FerrerInCode. Gendiag.exe SL
provided support in the form of salaries for authors Dr. CF-C and Dr.
PÁ, but did not have any additional role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. The remaining authors declare that they have no conflict
of interest.
References
1. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac
death. Circulation. 2012;125:620–37.
1024 J. Mates et al.
2. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert
consensus statement on the state of genetic testing for the chan-
nelopathies and cardiomyopathies this document was developed
as a partnership between the Heart Rhythm Society (HRS) and the
European Heart Rhythm Association (EHRA). Heart Rhythm.
2011;8:1308–39.
3. MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The
database of genomic variants: a curated collection of structural
variation in the human genome. Nucleic Acids Res. 2014;42
(Database issue):D986–992.
4. Toruner GA, Kurvathi R, Sugalski R, et al. Copy number varia-
tions in three children with sudden infant death. Clin Genet.
2009;76:63–8.
5. Norton N, Siegfried JD, Li D, Hershberger RE. Assessment of
LMNA copy number variation in 58 probands with dilated car-
diomyopathy. Clin Transl Sci. 2011;4:351–2.
6. Norton N, Li D, Rieder MJ, et al. Genome-wide studies of copy
number variation and exome sequencing identify rare variants in
BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet.
2011;88:273–82.
7. Eastaugh LJ, James PA, Phelan DG, Davis AM. Brugada syn-
drome caused by a large deletion in SCN5A only detected by
multiplex ligation-dependent probe amplification. J Cardiovasc
Electrophysiol. 2011;22:1073–6.
8. Barc J, Briec F, Schmitt S, et al. Screening for copy number
variation in genes associated with the long QT syndrome: clinical
relevance. J Am Coll Cardiol. 2011;57:40–7.
9. Herman DS, Lam L, Taylor MRG, et al. Truncations of titin
causing dilated cardiomyopathy. N Engl J Med.
2012;366:619–28.
10. Campuzano O, Sarquella-Brugada G, Mademont-Soler I, et al.
Identification of genetic alterations, as causative genetic defects in
long QT syndrome, using next generation sequencingtechnology.
PLoS ONE. 2014;9:e114894.
11. Bhuiyan ZA, van den Berg MP, van Tintelen JP, et al. Expanding
spectrum of human RYR2-related disease: new electrocardio-
graphic, structural, and genetic features. Circulation.
2007;116:1569–76.
12. Truszkowska GT, Bilińska ZT, Kosińska J, et al. A study in Polish
patients with cardiomyopathy emphasizes pathogenicity of phos-
pholamban (PLN) mutations at amino acid position 9 and low
penetrance of heterozygous null PLN mutations. BMC Med
Genet. 2015;16:21.
13. Lopes LR, Murphy C, Syrris P, et al. Use of high-throughput
targeted exome-sequencing to screen for copy number variation in
hypertrophic cardiomyopathy. Eur J Med Genet. 2015;58:611–6.
14. Campbell MJ, Czosek RJ, Hinton RB, Miller EM. Exon 3 deletion
of ryanodine receptor causes left ventricular noncompaction,
worsening catecholaminergic polymorphic ventricular tachy-
cardia, and sudden cardiac arrest. Am J Med Genet A.
2015;167A:2197–200.
15. Sonoda K, Ohno S, Otuki S, et al. Quantitative analysis of PKP2
and neighbouring genes in a patient with arrhythmogenic right
ventricular cardiomyopathy caused by heterozygous PKP2 dele-
tion. Europace. 2017;19:644–50.
16. Mademont-Soler I, Pinsach-Abuin ML, Riuró H, et al. Large
genomic imbalances in Brugada syndrome. PLoS ONE. 2016;11:
e0163514.
17. Ceyhan-Birsoy O, Pugh TJ, Bowser MJ, et al. Next
generation sequencing-based copy number analysis reveals low
prevalence of deletions and duplications in 46 genes associated
with genetic cardiomyopathies. Mol Genet Genom Med.
2016;4:143–51.
18. Mademont-Soler I, Mates J, Yotti R, et al. Additional value of
screening for minor genes and copy number variants in hyper-
trophic cardiomyopathy. PLos ONE. 2017;12:e0181465.
19. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommen-
dation of the American College of Medical Genetics and Geno-
mics and the Association for Molecular Pathology. Genet Med J
Am Coll Med Genet. 2015;17:405–24.
20. Li J, Lupat R, Amarasinghe KC, Thompson ER, et al. CONTRA:
copy number analysis for targeted resequencing. Bioinformatics.
2012;28:1307–13.
21. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-
wide copy number detection and visualization from targeted DNA
sequencing. PLoS Comput Biol. 2016;12:e1004873.
22. Hwang JA, Kim D, Chun SM, et al. Genomic profiles of lung
cancer associated with idiopathic pulmonary fibrosis. J Pathol.
2018;244:25–35.
23. Toffolatti L, Cardazzo B, Nobile C, et al. Investigating the
mechanism of chromosomal deletion: characterization of 39
deletion breakpoints in introns 47 and 48 of the human dystrophin
gene. Genomics. 2002;80:523–30.
24. Pfundt R, Del Rosario M, Vissers LELM, et al. Detection of
clinically relevant copy-number variants by exome sequencing in
a large cohort of genetic disorders. Genet Med J Am Coll Med
Genet. 2017;19:667–75.
25. Miller DT, Adam MP, Aradhya S, et al. Consensus statement:
chromosomal microarray is a first-tier clinical diagnostic test for
individuals with developmental disabilities or congenital anoma-
lies. Am J Hum Genet. 2010;86:749–64.
26. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South
ST, Working Group of the American College of Medical Genetics
Laboratory Quality Assurance Committee. American College of
Medical Genetics standards and guidelines for interpretation and
reporting of postnatal constitutional copy number variants. Genet
Med J Am Coll Med Genet. 2011;13:680–5.
27. Newman S, Hermetz KE, Weckselblatt B, Rudd MK. Next-
generation sequencing of duplication CNVs reveals that most are
tandem and some create fusion genes at breakpoints. Am J Hum
Genet. 2015;96:208–20.
28. Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na
(+) channel mutation causing both long-QT and Brugada syn-
dromes. Circ Res. 1999;85:1206–13.
29. Kalman L, Leonard J, Gerry N, et al. Quality assurance for
Duchenne and Becker muscular dystrophy genetic testing:
development of a genomic DNA reference material panel. J Mol
Diagn. 2011;13:167–74.
Role of copy number variants in sudden cardiac death and... 1025
